News

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

The annual meeting brought announcements and insights from companies in the retina care space.

Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing Nona's Harbour Mice platform, the collaboration aims to accelerate antibody discovery, focusing on innovative therapies for retinal and other eye conditions.

According to presentations at FLORetina ICOOR 2024 in Florence, Italy, data show promising early improvements in low luminance visual acuity, a key measure of visual function. A pivotal Phase 2/3 VISTA trial for laru-zova in XLRP is currently enrolling.

With cases of syphilitic uveitis on the rise, recognizing its varied presentations—including optic disc edema, which may appear without other significant eye inflammation—is increasingly important for timely diagnosis and treatment.

The Belgian B Corp company, founded in 2016, is partially owned by Rayner and distributed in over 20 European countries.

Clinicians must consider redefining the metrics and intention behind functional outcomes, according to experts from the European Association for the Study of Diabetic Eye Complications

Presentation closely resembled mitogen-activated extracellular signal-regulated kinase inhibitor–associated retinopathy

The use of ChatGPT may be premature to replace anterior segment experts.

A University of Colorado study links air pollution to increased ocular health issues, finding patient visits for irritation and allergies more than double during high particulate matter levels, emphasizing the need for proactive clinical strategies.

The report is titled, Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2034.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used hair dyes.

It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements and fundus examinations.

The annual meeting brought fourth announcements and insights from companies in the retina care space

Nerve cells in the retina were analyzed at the Vienna University of Technology using microelectrodes. According to researchers, the nerve cells demonstrated surprisingly stable behavior, which is good news for retina implants.

Ahead of this year's Floretina meeting and International Congress on OCT Angiography, En Face OCT and Advances in OCT (ICOOR), David Hutton of Ophthalmology Times spoke with Charles Wykoff, MD, PhD. At FLORetina ICOOR, he presented on a number of topics, including diabetic retinopathy—the subject of his conversation with the Eye Care Network.

According to researchers, GPT-4o demonstrates potential in generating comprehensive differential glaucoma diagnoses but falls short in primary diagnostic accuracy, underscoring its role as a complementary tool rather than a standalone diagnostic solution.

The authors searched PubMed, Scopus, MEDLINE, ScienceDirect, and ClinicalTrials.gov, and selected studies based on reports with an association between RVO and heart attack risk.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Dr Wykoff addressed the top three questions retina specialists have about retinal non-perfusion

ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8.

Kim served the Samsung Bioepis as Development Division Leader since December 2021.

The company begins phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and efficacy in ophthalmic models suggest potential for treating dry AMD, glaucoma, and neurodegenerative eye diseases.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

BostonSight’s pilot study, published in Clinical Ophthalmology, explores the use of PROSE scleral lenses as a drug delivery system for cyclosporine 0.05% in treating dry eye disease, showing promising symptom relief and tolerability.

This virtual key opinion leader (KOL) event will take place on Wednesday, December 11, 2024, at 4:00 PM ET.